Related Experiment Videos
Small-diameter PTFE portosystemic shunts: portocaval vs mesocaval
1Royal College of Surgeons of Edinburgh, United Kingdom.
Insights
Mesocaval interposition shunts using polytetrafluoroethylene prostheses effectively decompress portal pressure and prevent recurrent variceal bleeding in patients with liver disease. This surgical option demonstrates high shunt patency and survival rates with manageable encephalopathy.
Area of Science:
- Hepatology
- Vascular Surgery
- Gastroenterology
Background:
- Sclerotherapy failure in managing esophageal varices necessitates alternative treatment strategies.
- Portal hypertension management is critical for preventing variceal hemorrhage in patients with liver disease.
Purpose of the Study:
- To evaluate the efficacy and safety of small-lumen mesocaval interposition shunting in patients with failed sclerotherapy.
- To assess shunt patency, variceal bleeding recurrence, encephalopathy incidence, and survival rates.
Main Methods:
- Fifty-seven patients with failed sclerotherapy underwent mesocaval interposition shunt using polytetrafluoroethylene prostheses (10 or 12 mm).
- Patients were stratified by Child-Pugh grade (A or B) with specific liver volume parameters.
- Follow-up duration ranged from 16 months to over 6 years.
Main Results:
- Postoperative mortality was 5% (3 patients); 2 patients had early recurrent variceal hemorrhage.
- Cumulative shunt patency reached 95%, with a 9% incidence of encephalopathy managed medically.
- Actuarial survival at 6 years was 78% overall (88% for Child-Pugh A, 67% for Child-Pugh B).
Conclusions:
- Small-lumen mesocaval interposition shunting effectively decompresses the portal system and prevents recurrent variceal bleeding.
- The procedure demonstrates favorable shunt patency, low thrombosis rates, and acceptable encephalopathy incidence.
- This technique offers a viable option for portal decompression in selected patients with liver disease and failed prior treatments.
Abstract:
Fifty-seven patients with failed sclerotherapy received a mesocaval interposition shunt with an externally supported, ringed polytetrafluoroethylene prosthesis of either 10 or 12 mm diameter. Thirty-one patients had Child-Pugh grade A disease and 26 grade B; all had a liver volume of 1000-2500 ml. Follow-up ranged from 16 months to 6 years 3 months. Three patients (5 per cent) died in the postoperative period. There were two postoperative recurrences of variceal haemorrhage and one recurrent bleed in the second year after surgery. The cumulative shunt patency rate was 95 per cent and the incidence of encephalopathy 9 per cent; the latter was successfully managed by protein restriction and/or lactulose therapy. The actuarial survival rate for the whole group at 6 years was 78 per cent, for those with Child-Pugh grade A 88 per cent and for grade B 67 per cent. Small-lumen mesocaval interposition shunting achieves portal decompression, preserves hepatopetal flow, has a low incidence of shunt thrombosis, prevents recurrent variceal bleeding and is not associated with significant postoperative encephalopathy.